Networks, European Projects and Collaborations
Objectives
- To carry out studies in collaboration with national or internation groups of scientific excellence
- To disseminate, at European level, studies with considerable impact carried out by the team at national level
- To combat resistance to antibiotics by rationalizing their use in primary care centers or by optimizing hygiene measures in intensive care units
European Projects and Networks in Progress
- Genomics to combat resistance against antibiotics in Community-acquired LRTI in Europe (GRACE)
- Mastering of Hospital Antimicrobial Resistance (MOSAR) Surgical WP4
- Mastering of Hospital Antimicrobial Resistance (MOSAR) ICU WP3
- TheraEDGE: An Integrated Platform Enabling Theranostics Applications at the Point of Primary Care
- Network of Centers for Biomedical Research on Respiratory Diseases (Ciberes) of the Carlos III Health Institute (ISCIII)
Milestones Achieved
- Integration and participation in notable European groups working on respiratory infections
- Coordination of a Ciber group and national multicenter studies
- Coordination of the Corporate Research Program on Pneumonia of Ciberes for the period 2011-2014
Future Challenges
- Implementation and leadership, at European level, of a national multicenter study (in progress) on Health Care Associated Pneumonia
Publications
Moxifloxacin Monotherapy Is Effective in Hospitalized Patients with Community-Acquired Pneumonia: The MOTIV Study—A Randomized Clinical Trial
Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, and Read R, for the MOTIV (MOxifloxacin Treatment IV) Study Group
Clin Infect Dis. 2008; 46(10):1499-509
Markers of treatment failure in hospitalized community- acquired pneumonia
Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A
Thorax. 2008;63:447–452
Community-Acquired Pneumonia Organization (CAPO) Investigators, A worldwide perspective of atypical pathogens in community-acquired pneumonia.
Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, Blasi F, Fernandez P, File TM Jr, Jordi Rello Condomines, Rosario Menendez Villanueva, Marzoratti L, Luna CM, Ramirez JA.
Am J Respir Crit Care Med. 2007;175:1086–1093
Residency training of European respiratory medicine specialists: The HERMES project
Gema Tirado-Conde
Arch Bronconeumol. 2009 Feb;45(2):92-9
Geographic differences in clinical characteristics and management of COPD: the EPOCA study
Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, Joan B Soriano, Alejandra Ramirez-Venegas, Fanny WS Ko, Byron Canelos-Estrella, Eduardo Giugno, Miguel Bergna, Ivan Chérrez, Antonio Anzueto.
International Journal of COPD. 2008:3(4) 1–12.
Hemosiderin deposits confounds tracking of iron-oxide labelled stem cells
Rigol M, Solanes N, Roqué M, Farré J, Batlle M, Roura S, Bellera N, Prat-Vidal C, Sionis A, Ramírez J, Sitges M, Sanz G, Bayés-Genís A, Heras M.
Transpl Proc 2008; 40: 3619-3622.
Effects of Cyclosporine, Tacrolimus and Sirolimus on Vascular Changes related to immune response: an Experimental Study
Rigol M, Solanes N, Sionis A, Gálvez C, Martorell J, Rojo I, Brunet M, Ramírez J, Roqué M, E, Roig E, Pérez-Villa F, Barquín L, Pomar JL, Sanz G, Heras M.
J Heart Lung Transplant 2008; 27(4): 416-22.
Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs
Martinez-Olondris P, Rigol M, Soy D, Guerrero L, Agusti C, Quera MA, Li Bassi G, Esperatti M, Luque N, Liapikou M, Filella X, Marco F, de la Bellacasa JP, Torres A.
Crit Care Med. 2011 Sep 15.
Nursing home-acquired pneumonia: a 10 year single-centre experience
Polverino E, Dambrava P, Cillóniz C, Balasso V, Marcos MA, Esquinas C, Mensa J, Ewig S, Torres A.
Thorax. 2010 Apr;65(4):354-9.
Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial.
Little P, Stuart B, Moore M, Coenen S, Butler CC, Godycki-Cwirko M, Mierzecki A, Chlabicz S, Torres A, Almirall J, Davies M, Schaberg T, Mölstad S, Blasi F, De Sutter A, Kersnik J, Hupkova H, Touboul P, Hood K, Mullee M, O'Reilly G, Brugman C, Goossens H, Verheij T; on behalf of the GRACE consortium.
Lancet Infect Dis. 2013 Feb;13(2):123-129.
Lines list
- Animal Model
- Bronchiectasis non associated to Cystic Fibrosis (BQ-noFQ), Cystic Fibrosis (CF) and immune deficiencies
- Community-Acquired Pneumonia (CAP)
- Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
- Networks, European Projects and Collaborations
- Noninvasive Ventilation (NIV)
- Pulmonary complications in immunocompromised (IC) patients
- Translational research laboratory for advanced microbiology diagnosis and pathogen-host response in respiratory infections
- Ventilator-Associated Pneumonia (VAP)